Pfizer Inc. (NYSE: PFE) has been developing a COVID-19 vaccine for the past few months and so far it has observed positive findings in clinical trials. The company recently stated that data on the vaccine has so far demonstrated a good safety profile.
Pfizer is expected to provide more data on the pipeline coronavirus vaccine in October. Analysts are particularly keen on the data that the company will present because it will provide a rough idea of whether the company might roll out the vaccine before the end of the year. U.S President Donald Trump recently pointed out that he expects a coronavirus to be launched ahead of Election Day.
Does President Trump have insider information and does it point to Pfizer
Many viewed President Trump’s statement as a hint that one of the pharmaceutical companies developing a coronavirus vaccine might be planning to make the vaccine available to the masses in the next few weeks. Pfizer’s enthusiasm when it comes to the results of their clinical trials has provoked speculation that it is the pharmaceutical that Trump must have been hinting on. The company has been very transparent about the vaccine’s development.
"Transparency is a must, particularly given this situation and the politicization of the vaccine," stated. Albert Bourla, the CEO of Pfizer in a press statement.
Pfizer recently announced the expansion of its clinical trials to 44,000 from the previous 30,000 individuals. The expanded enrollment will consider teenagers above 16 years old and individuals suffering from diseases such as Hepatitis A, B or C, and other health conditions such as HIV.
The announcement could signal that previous clinical studies were favorable and the company wants to establish how the vaccine will fair in patients with the aforementioned illnesses. The upcoming data update to be released next month will be critical for determining whether Pfizer will be the first to offer a coronavirus vaccine.